AIDS 2010
18th International AIDS Conference (IAC)
July 18-23 2010
Vienna, Austria
- Vienna Intl AIDS Conference Thoughts from Jules Levin, NATAP – (07/23/10)
- Webcast Complications Plenary at IAC Vienna: The Double-Edged Sword: Long-Term Complications of ART and HIV – (08/29/10)
- IAC Summary on New Drugs and New Combinations – How will They Change What We Do? – Written by Joe Eron, Univ of North Carolina (08/16/10)
- A Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1 Infected Subjects: 48 Week Results – (08/15/10)
- Transmission of Integrase Strand-Transfer Inhibitor Multi-drug Resistant HIV: Case Report and Natural History of Response to Raltegravir-containing Antiretroviral Therapy – (08/15/10)
- Abacavir/Lamivudine with Fosamprenavir/Ritonavir or Efavirenz in Underrepresented, Antiretroviral-Naïve, HIV-Infected Subjects (SUPPORT): Tolerability, Safety, and Efficacy after 24 Weeks – (08/15/10)
- SWITCH-EE Study (Swiss-Cohort): A Randomized Cross-over Study to Compare Etravirine and Efavirenz treatment – (08/10/10)
- The SENSE Trial: Etravirine (ETR) shows fewer Neuropsychiatric Adverse Events than Efavirenz (EFV) in Treatment-naïve HIV-1 Infected Patients – (08/10/10)
- Efficacy of NGX-4010 (QUTENZA), an 8% capsaicin patch, in patients with HIV-associated distal sensory polyneuropathy: results of integrated analyses – (08/10/10)
- The SENSE trial: etravirine (ETR) QD shows fewer neuropsychiatric adverse events than efavirenz (EFV) in treatment-naïve HIV-1 infected patients – (08/10/10)
- Abacavir/lamivudine (ABC/3TC) with fosamprenavir/ritonavir (FPV/r) or efavirenz (EFV) in underrepresented, antiretroviral (ARV) naïve, HIV-infected subjects (SUPPORT): tolerability, safety, and efficacy after 24 weeks – (08/10/10)
- A pilot study of abacavir/lamivudine (ABC/3TC) and raltegravir (RAL) in antiretroviral naive HIV-1 infected subjects: 48-week results – (08/10/10)
- HBV related complications in HIV positive patients during HAART therapy – LAM resistance and high serum HBV-DNA & advancd liver disease – (08/10/10)
- Vienna Declaration: ‘decriminalize illicit drug use as an HIV prevention measure’ – (08/10/10)
- Highlights of the Vienna International AIDS Conference by Pablo Tebas, MD, University of Pennsylvania. – (08/07/10)
- High Prevalence of Bone Demineralization in a Cohort of HIV-Infected Postmenopausal Women – (08/06/10)
- Bioequivalence of the Co-Formulation of Emtricitabine/Rilpivirine/Tenofovir DF – (08/04/10)
- Pharmacokinetic interaction study between TMC278, a next-generation NNRTI, and methadone – (08/04/10)
- Switching from Kivexa [ABC/3TC ]+Kaletra [LPV/r] to Truvada [TDF/FTC]+Kaletra [LPV/r] Reduces High Cholesterol: Results of a 12 Week Randomized, Controlled Study (ROCKET II) – (08/04/10)
- Switching to Atripla (EFV/FTC/TDF) from ABC/3TC FDC (Kivexa/Epzicom) + Efavirenz (EFV) Improves Lipid Levels Towards NCEP Recommendations: Primary Endpoint Results of a 24-week Randomised Study – (08/04/10)
- The impact of switching to etravirine on efavirenz-related CNS toxicity – (08/04/10)
- Meta-analysis Shows Abacavir Has No Effect on Cardiovascular Adverse Events: Presented at AIDS 2010 – (08/04/10)
- Use of genotypic and maraviroc (MVC) clinical trial data to develop statistical models for predicting response to a MVC-containing regimen in a treatment-experienced (TE) population – (08/04/10)
- Low Risk of Malignancy With Maraviroc in Treatment-Experienced and Treatment-Naïve Patients Across the Maraviroc Clinical Development Program – (08/04/10)
- Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis: “34% Reduction in Mortality in Early Arm” – (08/04/10)
- Abacavir Use and Cardiovascular Disease Events: A Meta-Analysis of Published & Unpublished Data – (08/04/10)
- Darunavir/Ritonavir Monotherapy Fails Primary Noninferiority Test at MONET Week 96 – written by Mark Mascolini – (07/29/10)
- HIV Prevention at AIDS 2010 Vienna – written by Jared Baeten, MD PhD and Connie Celum, MD MPH University of Washington (07/29/10)
- Viral Control and Switch/Stop Rates Similar With ABC/3TC and TDF/FTC in Canada – written by Mark Mascolini – (07/27/10)
- Resistance and Bilirubin Derail Twice-Daily Raltegravir/Atazanavir – written by Mark Mascolini – (07/27/10)
- Tenofivir Once-Daily PrEP in MSM Friday Late Breaker – (07/27/10)
- The Monet Trial 96 Weeks: drunavir Monotherapy vs darunavir + 2 NRTIs inpatients with HIV RNA < 50 copies/ml at baseline – (07/27/10)
- Abacavir vs Tenofovir – Similar times to virologic suppression and switching or stopping for abacavir/3TC and tenofovir/FTC in naives in Canadian Observational Cohort Collaboration – (07/27/10)
- Coronary CT Sees Blockage in Half of HIV Group With No Heart Disease Symptoms – written by Mark Mascolini – (07/27/10)
- Small Study Suggests Once-Daily MVC Plus ATV/r as Viable First Regimen – written by Mark Mascolini – (07/26/10)
- Metabolic Marker Changes Similar After 12 Weeks of Darunavir and Atazanavir – written by Mark Mascolini – (07/26/10)
- HIV Infection Tied to Lower Risk of Vitamin D Deficiency in US Women’s Study – (07/26/10)
- Individual Antiretrovirals Not Tied to Vitamin D Deficiency in London HIV Clinic – (average age 48, 50% vit D low/deficient, 40% osteopenia, 13% oseoporosis) – (07/26/10)
- Infection With Resistant Virus More Than Doubles Risk of Virologic Failure – (07/26/10)
- HCV Co-infection is Associated with a High Risk of Osteoporotic Fractures Among HIV Patients – (07/26/10)
- 80% Prevalence of hypovitaminosis D and factors associated in a sample of HIV patients in Italy – (07/26/10)
- Oral Poster discussion: Shining Light on Vitamin D deficiency – (07/26/10)
- Benefits and Risks of Stepdown to Atazanavir/Ritonavir Plus Lamivudine – (07/23/10)
- HIV Raises Heart Disease Risk 60% in People Over 49 – (07/23/10)
- HAART Initiation and Clinical Outcomes: insights from the CASCADE Cohort on ‘When To Start’ – (07/23/10)
- Gardasil Effective in Preventing AIN and Anal Cancer Related to HPV: ‘Quadrivalent HPV Vaccine Efficacy against HPV 6/11/16/18 Infection and Disease in Men’ – (07/23/10)
- Association of Antiretroviral Therapy, Immunologic and Virologic Factors with Myocardial Infarction Rates in a U.S. Health Care System – (07/23/10)
- Nadir CD4 is a Predictor of HIV Neurocognitive Impairment (NCI) in the era of Combination Antiretroviral Therapy (CART): Results from the CHARTER Study – (07/23/10)
- Increased Rate of HIV Neurocognitive Impairment (NCI) among non-AIDS Cases in the Post-CART versus Pre-CART era – (07/23/10)
- Gardasil Effective in Preventing AIN and Anal Cancer Related to HPV: ‘Quadrivalent HPV Vaccine Efficacy against HPV 6/11/16/18 Infection and Disease in Men’ – (07/23/10)
- HPV Vaccine Prevents HPV Lesions and Infection in Men – written by Mark Mascolini – (07/22/10)
- Cognitive Impairment Rate Rising in HIV+ Without AIDS: CHARTER – written by Mark Mascolini – (07/22/10)
- Comparison of 48 week efficacy and safety of 400mg QD nevirapine (NVP) extended release formulation (Viramune XR) versus 200mg BID nevirapine immediate release formulation (Viramune IR) in combination with emtricitabine/tenofovir in antiretroviral (ARV) naïve HIV-1 infected patients (VERxVE) – (07/22/10)
- Once-Daily Maraviroc (MVC) + Atazanavir/Ritonavir(ATV/r) vs. Emtricitabine/Tenofovir(TDF/FTC) + ATV/r in Treatment Naïve Patients: A Week 24 Planned Interim Analysis – (07/22/10)
- The SPARTAN Study: A Pilot Study to Assess the Safety and Efficacy of an Investigational NRTI- and RTV-Sparing Regimen of Atazanavir (ATV) Experimental Dose of 300mg BID plus Raltegravir (RAL) 400mg BID (ATV+RAL) in Treatment-Naïve HIV-Infected Subjects – (07/22/10)
- VERxVE study demonstrates efficacy and safety of 400mg once daily nevirapine (Viramune) extended release (NVP XR) formulation – BI press release – (07/22/10)
- Pooled Week 48 efficacy and safety results from ECHO and THRIVE, two double-blind, randomised, Phase III trials comparing TMC278 versus efavirenz in treatment-naïve, HIV-1-infected patients – (07/22/10)
- TMC278 Noninferior to Efavirenz in Naive But With More Virologic Failures – written by Mark Mascolini – (07/22/10)
- Once-Daily S/GSK1349572 as Part of Combination Therapy in Antiretroviral Naïve Adults: Rapid and Potent Antiviral Responses in the interim 16-Week Analysis from SPRING-1 (ING112276) – (07/22/10)
- S/GSK1349572 Works Fast in Phase 2 Study of Treatment Naive – written by Mark Mascolini – (07/22/10)
- Nadir CD4 Count Strongly Predicts Neurocognitive Impairment in CHARTER – written by Mark Mascolini – (07/22/10)
- Two to Three Times Higher Hodgkin Risk in First Months of ART – written by Mark Mascolini – (07/22/10)
- Five Times Higher Risk of Intracranial Hemorrhage With HIV – written by Mark Mascolini – (07/22/10)
- Types of Kidney Problems May Be Changing as HAART Era Matures – written by Mark Mascolini – (07/22/10)
- Effects of Randomized Regimen and Nucleoside Reverse Transcriptase Inhibitor (NRTI) Selection on 96 Week Bone Mineral Density (BMD): Results from ACTG 5142 – (07/22/10)
- Concomitant nevirapine therapy is associated with higher efficacy of pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients – (07/22/10)
- METABOLIK (Metabolic Evaluation in Treatment-naïves Assessing the impact of two BOosted protease inhibitors on LIpids and other marKers): Comparison of the Metabolic Effects of Darunavir/ritonavir versus Atazanavir/ritonavir over 12Weeks – (07/22/10)
- Lipodystrophy and Inflammation Predict Grip Strength in HIV-Infected Men: the MACS Body Composition Sub-study – (07/22/10)
- New, Deadly, but Rare Encephalitis Described in 14 French HIV Patients – written by Mark Mascolini – (07/21/10)
- Low CD4s Trump Other MI Risk Factors in 6500-Person US Analysis – written by Mark Mascolini – (07/21/10)
- CDC Study Confirms Rising Non-AIDS Cancer Rate in With HIV – written by Mark Mascolini – (07/21/10)
- Cancer Rates in HIV+ in Atlanta: ‘Non-AIDS Cancers Found 10 to 15 Years Earlier in People With HIV’ – written by Mark Mascolini – (07/21/10)
- A Year of ART Does Not Ease Anal Cancer Harbingers in Men – written by Mark Mascolini – (07/21/10)
- Higher CD4 Count at Lung Cancer Diagnosis Predicts Survival – written by Mark Mascolini – (07/21/10)
- HCV SVR Rate Higher With Nevirapine Than Lopinavir in Multicenter Study – written by Mark Mascolini – (07/21/10)
- Congresswoman Barbara Lee Calls for $6 Billion for Global Fund – (07/21/10)
- S/GSK1265744: A Next Generation Integrase Inhibitor (INI) with Activity Against Raltegravir-Resistant Clinical Isolates – (07/21/10)
- Activity of the Next Generation Integrase Inhibitor S/GSK1349572 and Two First Generation Inhibitors Across a Broad Panel of HIV Subtype Isolates in PBMCs and MDMs – (07/21/10)
- HIV Integrase Genotypic and Phenotypic Changes Between Day 1 and Day 11 in Subjects with Raltegravir Resistant HIV Treated with S/GSK1349572: Results of VIKING Study – (07/21/10)
- ‘Start HIV Therapy Earlier, IAS-USA Panel Recommends’ – (07/20/10)
- Bill Clinton on HIV/AIDS: Much More Needs to be Done – (07/20/10)
- Bill Clinton, Gates: Fight AIDS more efficiently – (07/20/10)
- Tenofovir AIDS gel protects women in study – (07/20/10)
- Tenofovir Gel found to reduce AIDS risk in women – (07/20/10)
- New Tenofovir Gel Cuts Risk of HIV Infection for Women in Study – WSJ Report – (07/20/10)
- New Tenofovir Gel Cuts Risk of HIV Infection for Women in Study – WSJ Report – (07/20/10)
- Number Globally of HIV-positive in treatment rose by a quarter last year – (07/20/10)
- Gays With Well-Controlled HIV Not Protected From Lymphogranuloma Venereum – written by Mark Mascolini – (07/19/10)
- Long-Term Nonprogression Rare and Transient in Large CASCADE Cohort Study – written by Mark Mascolini – (07/19/10)
- Liver Death Rate in Spain Similar With and Without HIV, But Only in HCV-Negative – written by Mark Mascolini – (07/19/10)
- Death Rate Has Not Dropped in Certain Disadvantaged HIV+ US Groups – written by Mark Mascolini – (07/19/10)
- Fatal Liver Failure Still 8 Times More Common With HIV in Large US Cohort – written by Mark Mascolini – (07/19/10)
- HCV in HIV-Positives Raises Osteoporotic Fracture Risk Over 40% – written by Mark Mascolini – (07/19/10)
- Once- Versus Twice-Daily Raltegravir When Switching From a PI – written by Mark Mascolini – (07/19/10)
- Antioxidants With ART Boost CD4s, Ease Mitochondrial Damage in 8-Week Trial – written by Mark Mascolini – (07/19/10)
- Trading a Ritonavir-Boosted PI for Twice-Daily Raltegravir in SPIRAL – written by Mark Mascolini – (07/19/10)
- Abbott’s PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint – Abbott Press Release – (07/19/10)
- Impact of prior NRTI failure in the ODIS trial, a study conducted in HIV+ patients with undetectable viremia on protease inhibitors who switched to raltegravir qd versus bid – (07/19/10)
- TBR-652, a Potent Dual CCR5/CCR2 Antagonist in Phase 2 Development for Treatment of HIV Infection – Inflammation – (07/19/10)
- Tenofovir Gel Reduced HIV Transmission – pdf of Science Mag publication attached – (07/19/10)
- First-Line Lopinavir/r/Raltegravir (With No NRTIs) in Treatment Naive – written by Mark Mascolini – (07/19/10)
- Activity of Next Generation Integrase Inhibitor (INI) S/GSK1349572 in Subjects with HIV Exhibiting Raltegravir Resistance: Initial Results of VIKING Study (ING112961) – (07/19/10)
- Lopinavir/ritonavir (LPV/r) Combined with Raltegravir (RAL) Demonstrated Similar Antiviral Efficacy and Safety as LPV/r Combined with Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Treatment-Naïve HIV-1-Infected Subjects: PROGRESS 48 week results (07/19/10)
- Raltegravir Resistance Pattern Critical in Early Response to S/GSK1349572 – written by Mark Mascolini – (07/19/10)
- New IAS-USA Guidelines Urge Earlier Therapy for HIV Patients – (07/19/10)
- Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study – (07/19/10)
- AIDS group fears annual HIV costs may hit $35 bln – (07/19/10)
- HIV/AIDS numbers from around the world – (07/19/10)
- CDC Study Reports Poverty Among Minorities Doubles HIV Infection Rate – (07/19/10)
- Julio Montaner AIDS Conference Chief Lashes Out At World Leaders for Not Funding Global HIV – (07/19/10)
- 18th Int’l AIDS Conference opens in Vienna – (07/19/10)
- World AIDS Conference (IAC) Opens – to hear progress on drugs, money worries – (07/19/10)